<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032759</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00019279</org_study_id>
    <nct_id>NCT01032759</nct_id>
  </id_info>
  <brief_title>Memantine and Postoperative Pain</brief_title>
  <official_title>Memantine for Postoperative Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Memantine is associated with improvement in pain relief after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, controlled trial will investigate whether perioperative
      memantine has a postoperative analgesic effect following radical retropubic prostatectomy
      (RRP). 100-110 patients scheduled to undergo RRP at Duke will be assessed preoperatively for
      allodynia using Von Frey filaments, then stratified into two groups based on the presence or
      absence of allodynia. Patients in each group will then be randomized to receive either
      memantine 20 mg or placebo 30-60 minutes preoperatively, followed on postoperative day 1 with
      either memantine 10 mg in the morning and 10 mg in the evening for memantine patients, or
      placebo at the same intervals for placebo patients. Data such as morphine consumption,
      patient satisfaction and pain scores, opioid-related side effects, and the area of
      hyperalgesia around the surgical incision will be recorded for the initial 48 hours
      postoperatively, and patient satisfaction with their postoperative analgesia will be assessed
      after 1 week. At 1, 3, and 6 months postoperatively, patients will be asked about the
      presence and intensity of any persistent pain related to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hr Opioid Consumption</measure>
    <time_frame>24 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain score (0=no pain, 10= worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Related Side Effects</measure>
    <time_frame>0-24 h</time_frame>
    <description>Number of participants with postoperative nausea and vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Related Side Effects: Pruritus</measure>
    <time_frame>0-24 h</time_frame>
    <description>Number of participants who experienced pruritus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperalgesia</measure>
    <time_frame>Within 48 h</time_frame>
    <description>Stimulation with a Von Frey hair filament at 396 mN of force will be started from outside the hyperalgesic area, where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception. The first point where a &quot;painful,&quot; &quot;sore,&quot; or &quot;sharper&quot; feeling occurs will be marked, and the distance to the incision measured. The surface area will be measured in cm2 around the surgical incision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of participants who reported &quot;very satisfied&quot; or &quot;somewhat satisfied&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Post-surgical Pain</measure>
    <time_frame>1 month, 3 month, 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>20 mg, BID</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age 18 to 75 years old

        Exclusion Criteria:

          -  Chronic pain conditions or taking regular analgesics

          -  Taking psychotropic medications

          -  Parkinson's disease

          -  Narrow-angle glaucoma

          -  Known gastroduodenal ulcer

          -  History of seizure disorder

          -  Renal insufficiency, as defined by serum creatinine greater than 2 mg/dL

          -  Liver disease, including liver failure, cirrhosis, or acute hepatitis

          -  Significant coronary vascular disease or cardiac conduction system disease, as noted
             by ECG or history of cardiac symptoms, or cardiac ejection fraction less than 30%

          -  American Society of Anesthesiologists (ASA) score of 4 or higher

          -  Allergy to ketorolac or memantine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>January 19, 2016</results_first_submitted>
  <results_first_submitted_qc>February 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>77 participants signed consent, 63 participants were randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantine</title>
          <description>Memantine: 20 mg, BID</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24 Hour Assessment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 48 Hour Assessment</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantine</title>
          <description>Memantine: 20 mg, BID</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="7"/>
                    <measurement group_id="B2" value="59" spread="7"/>
                    <measurement group_id="B3" value="59" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores</title>
        <description>Pain score (0=no pain, 10= worst possible pain)</description>
        <time_frame>48 hours</time_frame>
        <population>Participants who completed the 48 hour assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>Pain score (0=no pain, 10= worst possible pain)</description>
          <population>Participants who completed the 48 hour assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="0.46"/>
                    <measurement group_id="O2" value="1.71" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24 hr Opioid Consumption</title>
        <time_frame>24 hr</time_frame>
        <population>Participants who completed the 24 hour assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>24 hr Opioid Consumption</title>
          <population>Participants who completed the 24 hour assessment.</population>
          <units>mg morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="3.9"/>
                    <measurement group_id="O2" value="18.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Related Side Effects</title>
        <description>Number of participants with postoperative nausea and vomiting.</description>
        <time_frame>0-24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Related Side Effects</title>
          <description>Number of participants with postoperative nausea and vomiting.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Related Side Effects: Pruritus</title>
        <description>Number of participants who experienced pruritus.</description>
        <time_frame>0-24 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Related Side Effects: Pruritus</title>
          <description>Number of participants who experienced pruritus.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperalgesia</title>
        <description>Stimulation with a Von Frey hair filament at 396 mN of force will be started from outside the hyperalgesic area, where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception. The first point where a “painful,” “sore,” or “sharper” feeling occurs will be marked, and the distance to the incision measured. The surface area will be measured in cm2 around the surgical incision.</description>
        <time_frame>Within 48 h</time_frame>
        <population>Number of participants who had this outcome measured and documented</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperalgesia</title>
          <description>Stimulation with a Von Frey hair filament at 396 mN of force will be started from outside the hyperalgesic area, where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception. The first point where a “painful,” “sore,” or “sharper” feeling occurs will be marked, and the distance to the incision measured. The surface area will be measured in cm2 around the surgical incision.</description>
          <population>Number of participants who had this outcome measured and documented</population>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="37"/>
                    <measurement group_id="O2" value="54" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Number of participants who reported &quot;very satisfied&quot; or &quot;somewhat satisfied&quot;</description>
        <time_frame>48 hours</time_frame>
        <population>Number of participants who had this outcome reported and documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Number of participants who reported &quot;very satisfied&quot; or &quot;somewhat satisfied&quot;</description>
          <population>Number of participants who had this outcome reported and documented.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Post-surgical Pain</title>
        <time_frame>1 month, 3 month, 6 month</time_frame>
        <population>Data was not collected and therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Memantine</title>
            <description>Memantine: 20 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: BID</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Post-surgical Pain</title>
          <population>Data was not collected and therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Memantine</title>
          <description>Memantine: 20 mg, BID</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TIA</sub_title>
                <description>Transient ischemic attack</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ashraf Habib</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>9196686266</phone>
      <email>habib001@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

